ApprovedFDA approval

Orzeyful (oveporexton)

Takeda Pharmaceuticals USA (TAK)

Marketer take

The first orexin agonist for narcolepsy type 1, a new mechanism that sleep specialists will weigh against oxybates and wake-promoting agents, so expect mechanism-of-disease education.

Sponsor company
Takeda Pharmaceuticals USA (TAK)
Indication
To treat narcolepsy type 1
Therapeutic area
Neurology, Sleep
Event
FDA approval
Date
Aug 5, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move